Bausch Health signals 2026 revenue of $5.525B-$5.625B as it outlines Q4 Xifaxan headwinds (NYSE:BHC)
· seekingalpha.com
Bausch Health Q3 2026 earnings: raised guidance, topped $1B EBITDA, cut debt, but flagged Q4 Xifaxan headwinds.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...